✦ LIBER ✦

Immunotherapy for malignant melanoma: A review and update

✍ Scribed by J. Michael C. Mcgee

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 421 KB
Volume: 7
Category: Article
ISSN: 8756-0437
DOI: 10.1002/ssu.2980070407

No coin nor oath required. For personal study only.

✦ Synopsis

Several different approaches to the application of specific active immunotherapy for the adjuvant therapy of melanoma have developed independently. Specific active immunotherapy refers to autologous or allogenic inoculation or transplantation of tumor cells or cell products into patients with cancer. Several different types of tumor vaccines have been studied and have been combined with different immunotherapeutic modalities. This report will include a review of several of those different techniques and will also review the observed 5-year survival rates for a melanoma tumor homogenate (concentrated) vaccine, developed by L. J. Humphrey and colleagues.

📜 SIMILAR VOLUMES

BCG immunotherapy for recurrent malignan

BCG immunotherapy for recurrent malignant melanoma

✍ Shelley L. Rasmussen; Jordan U. Gutterman; Evan M. Hersh; Sydney Boston; M. Mars 📂 Article 📅 1980 🏛 Springer-Verlag 🌐 English ⚖ 789 KB

A study was made of immunologic parameters obtained from patients with stage IIIB malignant melanoma who were treated with BCG. Patients with the longest disease-free interval and survival times were those who had small initial skin test reactions and developed larger reactions during the course of

Adjuvant immunotherapy of malignant mela

Adjuvant immunotherapy of malignant melanoma

✍ Gerard V. Aranha; Charles F. McKhann; Theodor B. Grage; Audolfur Gunnarsson; Ric 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 561 KB

Experimental trials of immunotherapy for

Experimental trials of immunotherapy for malignant melanoma

✍ Douglas Reintgen; Jeanne Becker; Hilliard F. Seigler 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 809 KB

Conventional treatment for metastatic melanoma consists of surgical resection, chemotherapy, and radiation therapy. New approaches toward treatment of this disease include the development of passive and active immunotherapeutic regimens. Malignant melanoma is particularly amendable to immunotherapy

Immunotherapy of malignant melanoma. A c

Immunotherapy of malignant melanoma. A clinical trial

✍ W. H. McCarthy; G. Cotton; A. Carlon; G. W. Milton; S. Kossard 📂 Article 📅 1973 🏛 John Wiley and Sons 🌐 English ⚖ 711 KB

Malignant cutaneous melanoma: A review

✍ R. B. Wright; D. H. Clark; J. A. Milne 📂 Article 📅 1953 🏛 John Wiley and Sons 🌐 English ⚖ 1015 KB

Update on active specific immunotherapy

Update on active specific immunotherapy with melanoma vaccines

✍ Conforti, Arnold M.; Ollila, David W.; Kelley, Mark C.; Gammon, Guy; Morton, Don 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Although a randomized clinical trial has yet to show a statistically significant improvement in the survival of patients receiving vaccine therapy for malignant melanoma, several studies have shown enhanced survival of patients developing an immune response to a melanoma vaccine. The knowledge and t